Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-L1 anticorps (AA 19-238)

PD-L1 Reactivité: Humain WB, IHC, IF Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN1512699
  • Antigène Voir toutes PD-L1 Anticorps
    PD-L1 (CD274 (PD-L1))
    Épitope
    • 29
    • 16
    • 15
    • 13
    • 11
    • 10
    • 9
    • 7
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 19-238
    Reactivité
    • 170
    • 108
    • 63
    • 7
    • 6
    • 5
    • 5
    • 1
    • 1
    Humain
    Hôte
    • 126
    • 62
    • 17
    • 4
    • 4
    • 1
    Lapin
    Clonalité
    • 107
    • 105
    • 2
    Polyclonal
    Conjugué
    • 98
    • 16
    • 13
    • 11
    • 9
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Cet anticorp PD-L1 est non-conjugé
    Application
    • 138
    • 104
    • 60
    • 40
    • 37
    • 28
    • 17
    • 17
    • 16
    • 14
    • 10
    • 7
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)
    Séquence
    FTVTVPKDLY VVEYGSNMTI ECKFPVEKQL DLAALIVYWE MEDKNIIQFV HGEEDLKVQH SSYRQRARLL KDQLSLGNAA LQITDVKLQD AGVYRCMISY GGADYKRITV KVNAPYNKIN QRILVVDPVT SEHELTCQAE GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFNVTSTLR INTTTNEIFY CTFRRLDPEE NHTAELVIPE LPLAHPPNER
     Réactivité croisée
    Humain, Souris, Rat
    Attributs du produit
    Polyclonal Antibodies
    Purification
    Affinity purification
    Immunogène
    Recombinant fusion protein containing a sequence corresponding to amino acids 19-238 of human PD-L1/CD274 (NP_054862.1).
    Isotype
    IgG
    Top Product
    Discover our top product PD-L1 Anticorps primaire
  • Indications d'application
    WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Conseil sur la manipulation
    Avoid freeze / thaw cycles
    Stock
    -20 °C
    Stockage commentaire
    Store at -20°C. Avoid freeze / thaw cycles.
  • Antigène
    PD-L1 (CD274 (PD-L1))
    Autre désignation
    PD-L1 (PD-L1 Produits)
    Synonymes
    anticorps B7-H, anticorps B7H1, anticorps PD-L1, anticorps PDCD1L1, anticorps PDCD1LG1, anticorps PDL1, anticorps A530045L16Rik, anticorps B7h1, anticorps Pdcd1l1, anticorps Pdcd1lg1, anticorps Pdl1, anticorps RGD1566211, anticorps CD274 molecule, anticorps CD274 antigen, anticorps programmed cell death 1 ligand 2, anticorps CD274, anticorps Cd274, anticorps PDCD1LG2
    Sujet
    This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.,B7-H,B7H1,PDL1,PD-L1,PDCD1L1,PDCD1LG1,CD274,Immunology & Inflammation,CD markers,PD-L1
    Poids moléculaire
    20 kDa/33 kDa
    ID gène
    29126
    UniProt
    Q9NZQ7
    Pathways
    Cancer Immune Checkpoints
Vous êtes ici:
Support technique